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Abstract
Background: Several conservative (i.e., nonpharmacologic, nonsurgical) treatments exist for secondary
lymphedema. The optimal treatment is unknown. We examined the effectiveness of conservative treatments for
secondary lymphedema, as well as harms related to these treatments.
Methods: We searched MEDLINE
®, EMBASE
®, Cochrane Central Register of Controlled Trials
®, AMED, and CINAHL
from 1990 to January 19, 2010. We obtained English- and non-English-language randomized controlled trials or
observational studies (with comparison groups) that reported primary effectiveness data on conservative
treatments for secondary lymphedema. For English-language studies, we extracted data in tabular form and
summarized the tables descriptively. For non-English-language studies, we summarized the results descriptively and
discussed similarities with the English-language studies.
Results: Thirty-six English-language and eight non-English-language studies were included in the review. Most of
these studies involved upper-limb lymphedema secondary to breast cancer. Despite lymphedema’s chronicity,
lengths of follow-up in most studies were under 6 months. Many trial reports contained inadequate descriptions of
randomization, blinding, and methods to assess harms. Most observational studies did not control for confounding.
Many studies showed that active treatments reduced the size of lymphatic limbs, although extensive between-
study heterogeneity in areas such as treatment comparisons and protocols, and outcome measures, prevented us
from assessing whether any one treatment was superior. This heterogeneity also precluded us from statistically
pooling results. Harms were rare (< 1% incidence) and mostly minor (e.g., headache, arm pain).
Conclusions: The literature contains no evidence to suggest the most effective treatment for secondary
lymphedema. Harms are few and unlikely to cause major clinical problems.
Background
Secondary lymphedema (SE) is an acquired condition
resulting from disease, trauma, or an iatrogenic process
such as surgery or radiation that damages the lymphatic
system [1,2]. Clinically, SE may present as edema [3].
Globally, the major cause of SE is lymphatic filariasis
resulting from infection with the nematode Wusheria
Bancrofti. In the United States (U.S.), the most common
cause of SE is treatment for malignancy (i.e., surgery,
radiation) [4], especially breast cancer. SE incidence
rates following mastectomy range from 24% to 49%,
with lower rates of 4% to 28% following lumpectomy
[1]. The literature is bereft of reliable prevalence
estimates, although some suggest approximately 10 mil-
lion persons in the U.S. have SE http://www.shlnews.
org/?p=67.
Several types of conservative therapy exist to treat SE.
Compression techniques, including multilayer banda-
ging, and pressure garments are thought to restore
hydrostatic pressure and improve lymph flow in affected
limbs [5]. Manual lymphatic drainage (MLD), a form of
massage, is administered using light strokes to direct
lymph flow from blocked to open lymphatics [5-7].
Exercise helps increase lymph flow via muscle contrac-
tion around the lymphatics [8]. Complex (or complete)
decongestive therapy (CDT) includes MLD, limb com-
pression with low stretch bandages, skin care, and exer-
cise. The intent of CDT is to decrease fluid in affected
limbs, prevent infection, and improve tissue integrity
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medium, provided the original work is properly cited.[5,9]. Dieting (e.g., low-fat diet) is also used as a conser-
vative therapy for SE.
Mechanical treatments for SE include intermittent
pneumatic compression (IPC) devices and low-level
laser therapy (LLLT). IPC devices are pneumatic cuffs
connected to pumps that mimic the naturally occurring
muscle pump effect of muscles contracting around per-
ipheral lymphatics [10]. LLLT employs low intensity
laser waves and appears to encourage formation of lym-
phatic vessels, promote lymph flow, and stimulate
immune systems [11,12].
This systematic review is based on a peer-reviewed
technology report [13] commissioned by the Agency for
Healthcare Research and Quality (AHRQ) and the Cen-
ters for Medicare and Medicaid Services (CMS). A copy
of the technology report is available on the AHRQ web-
site http://www.cms.gov/determinationprocess/down-
loads/id66aTA.pdf. The technology report served as
background material for a Medicare Evidence Develop-
ment & Coverage Advisory Committee (MEDCAC)
Meeting held in November 2009. One purpose of the
meeting was to discuss the available evidence for treat-
ment methods in SE.
This review addresses two key questions:
1. How effective are conservative treatments for SE in
pediatric or adult populations who developed SE follow-
ing any type of illness except filariasis infection?
2. What harms are associated with conservative treat-
ments for SE?
Methods
Data sources and selection
We searched MEDLINE
®, EMBASE
®, Cochrane Central
Register of Controlled Trials
®,A M E D ,a n dC I N A H L
from 1990 to January 19, 2010. We exploded the subject
heading ‘lymphedema’ a n ds e a r c h e di ta sat e x t w o r d
(’lymphedema’ or ‘lymphoedema’). The complete litera-
ture search strategy is depicted in Additional file 1
Methods S1. We initially searched the English-language
literature and later searched the non-English literature
following recommendations of persons who peer
reviewed our technology report [13]. The purpose of
exploring non-English studies was to assess whether
they contained information to supplement the English-
language studies. We also searched the reference lists of
extracted studies and previously published systematic
reviews [1,12,14-16].
Criteria for considering studies for this review
We included studies provided they were randomized
controlled trials (RCTs) or observational studies with
comparison groups (e.g., cohort, case control). We also
included studies of pediatric and adult patients who
received treatment for SE following any form of illness
except filariasis infection. We excluded case series, case
reports, narrative and systematic reviews, editorials,
comments, letters, opinion pieces, abstracts, conference
proceedings, and animal experiments. We also excluded
studies involving pharmacologic or surgical treatments
for SE.
Trained raters independently applied the inclusion and
exclusion criteria to the articles retrieved in the litera-
ture search. The criteria were applied at three levels of
screening: I-title and abstract first review; II-title and
abstract second review; III-full text. We extracted data
from articles that passed full text screening. Raters man-
aged the screening process electronically using standar-
dized screening forms and Distiller SR systematic review
software (Evidence Partners, Ottawa, Canada).
Methodological quality assessment
Two raters independently assessed the quality of the
extracted English-language articles. Raters used the
eight-point Jadad scale for RCTs [17,18] and the New-
castle-Ottawa Scale (NOS) [19] for observational studies.
The overall quality of each extracted article was rated
‘good’, ‘fair’,o r‘poor’ in accordance with the recommen-
dations outlined in the AHRQ’sm e t h o d sg u i d ef o rs y s -
tematic reviews [20].
Issues of methodological quality often preclude the
inclusion of observational studies in systematic reviews.
However, observational studies may be included to help
overcome evidence gaps in RCTs, especially in the
assessment of harms [20].
Data extraction
A meta analysis was infeasible because the extracted stu-
dies exhibited substantial clinical and methodological het-
erogeneity. Therefore, we used a descriptive approach to
answer the key questions. This approach involved extract-
ing English-language data into tables and developing writ-
ten summaries of the English and non-English evidence.
For English-language articles, we extracted data on
study design, type of treatment, sample size, cause of
SE, definition of SE, study inclusion/exclusion criteria,
and outcome data. While we did not extract data from
the non-English articles, we summarized the main con-
tents of these articles in writing and compared them to
the extracted English-language articles.
Role of the funding source
The McMaster University Evidence-based Practice Cen-
tre researched and wrote the initial technology report
under contract with the AHRQ, which gave us permis-
sion to publish this manuscript. The AHRQ and CMS
had no role in the literature search, data analysis, study
conduct, manuscript preparation, or interpretation of
results.
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Figure 1 depicts the flow of studies through screening.
Thirty-six English-language and eight non-English-lan-
guage studies passed screening. Table 1 contains basic
information on the English-language studies; Table 2
shows extracted English-language data relevant to
answering the two key questions listed above.
Methodological quality assessment
Of the 36 English-language studies, 30 were RCTs
[11,21-41,43-50] and six were observational (cohort)
[51-56]. Fifteen RCTs were fair quality [21,22,25,26,
29-32,36,43-47,50], eight were good quality [11,24,27,35,
38,41,48,49], and seven were poor quality [23,28,33,34,
37,39,40]. Among the observational studies, three were
good quality [52,54,55] and three were poor quality
[51,53,56].
The major quality issues with the RCTs were inade-
quate description of randomization processes in about
half the studies, no reports of double blinding in a
majority of the studies, and no discussion of methods to
assess harms in most studies.
For the observational studies, the major quality issue
was related to confounding. Four of the six studies
[52,54-56] did not report attempts to control confound-
ing. The authors of two studies [51,53] controlled
potential confounding by matching on SE severity.
Summary of extracted studies
Thirty-two of 36 English-language studies included par-
ticipants with lymphedema secondary to breast cancer
[11,21,22,24-32,34-41,43-52,54,55]. Some studies speci-
fied that participants had to be in remission, have no
relapse, or have no metastases [21,22,24,26,29,
35,41,43,44,46-48]. Five studies defined SE as ‘mild’
[21,22], ‘chronic’ [47], or ‘moderate to severe’ [24,48].
Sample sizes ranged from eight [32] to 150 [51].
Intervals between study participants’ completion of
cancer treatment and recruitment into the extracted stu-
dies varied considerably, e.g., 3 to 6 weeks [36], at least
3 months [46], at least 4 months [21,29], at least 6
months [22,27], at least 12 months [24,43,44], between 1
month and 1 year [47], or at least 4 years [30]. We also
found variation in elapsed times between SE symptom
onset and study recruitment, e.g., at least 3 months
[32,34], greater than 3 months [50], a median of 9 to
10.5 months [31], less than 1 year [26], less than or
equal to 2 years [25], or 0 to 5 years [49].
Follow-up periods varied considerably between studies,
with little relation between follow-up length, study type,
or intervention. Many studies ended immediately after
the treatment regimen, although five studies followed
patients for up to 1 year [34,41,51,53,54]. The shortest
study lasted 24 h [24].
Several RCTs did not clearly label treatments as ‘com-
parator’ or ‘experimental’ (e.g., a study of IPC and MLD
[31]). For this review, we assumed the comparators were
the more conservative therapies. Common conservative
therapies in RCTs were “usual care”, sham treatment, or
no treatment [11,26,27,32,36,37,43,44,52]. ‘Active’ treat-
ment comparators included complex decongestive ther-
apy [28,46,47], elastic sleeve [21,22,52], self-massage
[49], bandaging alone [24,38], “simple lymphatic drai-
nage” [45,50], IPC [34], MLD [23,30], or physiotherapy
[33].
In the observational studies, comparators included
IPC, compression garment, MLD, or no active treatment
[51-56].
Many RCTs measured outcomes using limb volume or
circumference [22,26,32,34,36,40]. Other outcomes
included subjective symptoms such as pain, heaviness,
or tension [28,30-32,34,36,55], range of joint motion
(usually shoulder) [11,21,29-32,46], grip strength [31,34],
measurements of intra- and extra-cellular fluid levels
through bioimpedance [11,27], skin-fold thickness
[43,44], and skin tonicity using tonometry [11,46,47].
Some studies attempted to correlate results of SE treat-
ment with changes in quality of life [37,49].
For the observational studies, outcomes included limb
volume [51-53,55,56], skin firmness [51], subjective
assessments of body weight [55], limb circumference
[56], and a vaguely described scale of ‘psychic well-
being’ and ‘physical complaints’ [54].
How effective are conservative treatments for SE in
pediatric or adult populations who developed SE
following any type of illness except filariasis infection?
Two RCTs showed IPC had benefits over CDT or self-
massage [46,49]. Three other RCTs failed to show
superiority of IPC compared to lymphatic massage [31],
skin care [26], or elastic sleeve [22]. One RCT showed
Title and Abstract Screen #1
                n=6,814
Title and Abstract Screen #2
                n=703
Excluded n=6,111
Full Text Screen
       n=231
  
Included Articles
n = 44
(n = 36 English;
n = 8 non-English)
Excluded n=187
Article not available....................................... n=13
Narrative review, editorial, 
primary lymphedema, commentary............... n=38
Prevention..................................................... n=3
Incidence/Prevalence Lymphedema............. n=1
Companion.................................................... n=1
No control group............................................ n=19
Not effectiveness study................................. n=4
Not stratified by primary/secondary          
lymphedema.................................................. n=11
Diagnosis-related, not treatment related....... n=97
Excluded n=472
Figure 1 Study flow diagram.
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Study
(Quality
†)
Sample Size
(Treatment +
Control)
1) Cause of SE
2) Definition of SE
1) Time of SE Onset
2) Time of Tx initiation
3) Criteria to Start/stop Tx
Other Inclusion/Exclusion Criteria
RCT
Andersen
2000 [21]
Denmark
Fair (4)
20 + 22 1) BCa Tx
2)≥ 200 ml volume or ≥ 2c m
circumference difference between
arms
1) After surgery
2)≥ 4 month post-BCa Tx
3) SE Dx/NR
Exclusion:
- bilateral BCa
- SE Tx < 3 months
- BCa recurrence
- severe SE (volume difference >
30%)
Bertelli
1991 [22]
Italy
Fair (4)
37 + 37 1) BCa Tx
2)> 10 cm and < 20 cm
circumference difference between
arms (mild SE)
1) Limb circumference ≥ 25%
compared to baseline
2) NS
Inclusion:
- no metastases or relapse
-n oT x≤ 6 months
- no lymphangitis
Exclusion:
- wearing cardiac stimulator
- currently receiving CT or RT
Bialoszewski
2009 [23]
Poland
Poor (3)
12 + 12 1) Lower extremity SE post-leg
lengthening surgery
2) Physical examination and
radiographic images to Dx SE
1) Following leg lengthening surgery
2) Post-surgery
3) Lower extremity SE/NR
Inclusion:
-age 15-40 years
Carati
2003 [11]
Australia
Good (8)
37 + 27 1) BCa Tx
2)> 200 ml volume or ≥ 2c m
circumference difference between
arms
1) NR
2) NR
3) SE Dx/NR
Inclusion:
- female
Exclusion:
- co-morbidities present
- significant change ≤ 3 months
- unable to manipulate arm
- primary SE
Damstra
2009 [24]
Netherlands
Good (6)
18 + 18 1) BCa Tx
2) Moderate to severe SE (ISL
definition)
1) 3-50 month post-surgery
2)≥ 12 month post-surgery
3) SE Dx/NR
Inclusion:
-female
-> 18 years
-12 months post BCa Tx without
reoccurrence
Exclusion:
-allergy to materials
-systemic diseases
-arterial/venous disease
Didem
2005 [25]
Turkey
Fair (5)
27 + 26 1) BCa Tx
2) Arm circumference difference
2-5 cm
1)> 1 year after surgery
2) 3 year post-surgery
3) SE Dx/NR
Inclusion:
-S E≥ 1 year
Exclusion:
- psychiatric
illness
- pain in axillary region
- cardiac disease
- uncontrolled hypertension
- malignancy
Dini
1998 [26]
Italy
Fair (5)
40 + 40 1) BCa Tx
2) Arm circumference difference
of 2-5 cm
1)< 1 year
2)> 1 year after SE
3) SE Dx/difference in circumference >
10 cm in affected vs. unaffected limb/
occurrence of harms
Inclusion:
-S E≥ 1 year
- no lymphangitis, no evidence of
local or distant relapse, no other
serious or psychiatric illness
Exclusion:
- prior SE therapy
- bilateral breast surgery
- bilateral axillary node dissection
Hayes
2009 [27]
Australia
Good (6)
16 + 16 1) BCa Tx
2) Health professional diagnosis
1) NR
2)≥ 6 month after BCa Tx
3) SE Dx/occurrence of harms
Inclusion:
-< 76 years
- Unilateral BCa Tx ≥ 6 months ago
- able to travel to clinic
Hou
2008 [28]
China
Poor (3)
15 + 35 1) BCa Tx
2) NR
1) NR
2)> 5 year post-surgery
3) SE Dx/NR
Exclusion:
- radiotherapy
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Irdesel
2007 [29]
Turkey
Fair (5)
10 + 11 1) BCa Tx
2) NR
1) 3-60 month
2)> 4 month post-BCa surgery
3) SE Dx/NR
Exclusion:
-BCa operation < 4 months ago
-recurrence or bilateral BCa
-stage 4 BCa
-elephantiasis
-congestive heart failure
-deep vein thrombosis
-acute infection
Jahr
2008 [30]
Germany
Fair (5)
11 + 10 1) BCa Tx
2) NR
1) NR
2) ~4 year post-surgery
3) SE Dx/NR
Inclusion:
- age 18-80 years
- living near study center
-≥ 6 weeks since RT
Exclusion:
-T x≤ 3 months ago
- acute inflammation
- acute thrombosis
- heart disease
- electronic implant
- pregnant
- sensitivity to electric fields
Johansson
1998 [31]
Sweden
Fair (4)
14 + 14 1) BCa Tx
2)> 10% difference in affected vs.
unaffected arm
1) Median 9-10.5 month
2) Median 9-10.5 month
3) SE Dx/NR
Exclusion:
- previous contralateral breast
disease
- comorbidity affecting swollen arm
- treatment ≤ 6 months (except
compression sleeve)
- SE resolved during initial
compression sleeve use
Kaviani
2006 [32]
Iran
Fair (5)
4 + 4 1) BCa Tx
2)≥ 2 cm swelling in affected arm
1) 3 month
2) SE ≥ 3 month
3) SE Dx/NR
Inclusion:
- no contraindications to laser
Exclusion:
- metastatic disease
Kessler
2003 [33]
Switzerland
Poor (3)
11 + 12 1) Ankle surgery
2) Clinically diagnosed post-
operative swelling
1) NR
2) 2nd day post-surgery
3) Post-operative swelling/NR
- Age: 18-75 year
- good physical condition
- no contraindications for lymph
drainage
Kozanoglu
2009 [34]
Turkey
Poor (3)
25 + 25 1) BCa Tx
2) Difference > 2 cm at 3/7
measurement points on limb
1)> 3 month
2) SE > 3 month
3) SE Dx/NR
Inclusion:
- arm SE ≥ 3 months
Exclusion:
- metastases or ongoing RT
- cellulitis
- venous thrombosis
- inflammatory disease
- history of severe trauma
- photosensitivity
- medications that affect electrolyte
balance
- limitation in UE joints
- physical therapy other than skin
care
- home exercises for SE in past 6
months
Lau
2009 [35]
China
Good (6)
11 + 10 1) BCa Tx
2) Arm volume difference > 200
ml
1) 22-60 month post-BCa
2) Post-BCa Tx
3) SE Dx/NR
Inclusion:
-≥ 18 years
- unilateral mastectomy + CT or RT
Exclusion:
- metastases
- history of arm trauma
- kidney, heart, or lung disorder
- medications that alter body fluids
- primary SE of lower limb
- decrease shoulder movement
- cellulitis ≤ 3 months
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Maiya
2008 [36]
India
Fair (5)
10 + 10 1) BCa Tx
2)≥ 2 cm difference at any 2
points between affected and
unaffected limbs
1) NR
2) 3-6 week post-mastectomy
3) SE Dx/NR
Inclusion:
- mastectomy or RT completion
Exclusion:
- primary SE
- limb infection
McKenzie
2003 [37]
Canada
Poor (3)
7 + 7 1) BCa Tx
2) Circumference difference is > 2
cm and < 8 cm
1) NR
2)> 6 month post-cancer Tx
3) SE Dx/NR
Exclusion:
- stage III SE
- bilateral disease
- medications that affect swelling
McNeely
2004 [38]
Canada
Good (6)
22 + 20 1) BCa Tx
2)≥ 150 ml difference between
affected and unaffected arms
1) NR
2) NR
3) SE Dx/NR
Inclusion:
- no sleeve use < 4 months
-≥ 6 months since SE T
XExclusion:
- new cancer D
X- receiving RT or CT
- infection in SE limb
- contraindications to T
X- uncontrolled hypertension
- heart disease
- renal insufficiency
- venous thrombosis
Pilch
2009 [39]
Poland
Poor (3)
1 7+9+1 1+
20
1) BCa Tx
2) NR
1) NR
2) NR
3) SE Dx/NR
Inclusion:
-age 39-80 years
Radakovic
1998 [40]
Yugoslavia
Poor (1)
18 + 18 1) BCa Tx
2) NR
1) NR
2) post-RT
3) SE Dx/NR
Inclusion:
- no metastases
Schmitz
2009 [41]
U.S.
(companion
Schmitz [42])
Good (7)
71 + 70 1) BCa Tx
2)≥ 10% volume or circumference
difference between affected and
unaffected arms
1) NR
2) 1-15 year post-BCa
3) SE Dx/SE exacerbation or cancer
recurrence
Inclusion:
- 1-15 years since BCa D
X- no evidence of cancer
- unilateral SE
- BMI < 50 kg/m
2
- not actively trying to lose weight
- no medical conditions to limit
exercise
- no weight lifting ≤ 1 year
- removal of at least one lymph
node
Shaw
2007 [43]
U.K.
Fair (5)
11 + 10 1) BCa Tx
2) Affected arm volume ≥ 15%
than unaffected arm
1) NR
2)≥ 12 month post-CT or RT
3) SE Dx/completion of therapeutic
regimen
Inclusion:
- remission
- BMI ≥ 25 kg/m
2
Shaw
2007 [44]
U.K.
Fair (5)
19 + 17 + 15 1) BCa Tx
2) Affected arm volume ≥ 20%
than unaffected arm
1) NR
2)≥ 12 month post-cancer Tx
3) SE Dx/NR
Inclusion:
- remission
Sitzia
2002 [45]
U.K.
Fair (5)
15 + 13 1) BCa Tx
2) Moderate or severe edema (≥
20%)
1) NR
2) NR
3) SE Dx/NR
Inclusion:
-≥ 18 years
- no active disease
- no Tx except support garment
Szuba
2002 [46]
U.S.
Fair (4)
12 + 11 1) BCa Tx
2) Affected arm volume ≥ 20%
than unaffected arm
1) NR
2)≥ 3 month from BCa Tx
3) SE Dx/NR
Inclusion:
-≥ 12 week post T
XExclusion:
- active infection
- recurrence
- venous occlusion
Szuba
2002 [47]
††
U.S.
Fair (4)
12 + 13 1) BCa Tx
2) NR
1) NR
2) 1-12 month
3) SE Dx/NR
Inclusion
- CDT completed 1-12 months ago
Exclusion:
- active infection
- recurrence
- venous occlusion
- bilateral SE
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edema than a one-chamber sleeve [39].
Six RCTs used some form of massage-based therapy
as the study treatment. Of these, only one suggested
benefits in the massage group [25]. Other studies found
no differences between massage and bandaging alone
[38], elastic sleeve [21], or a less intensive form of mas-
sage [45,50].
In three studies of laser treatment, laser was superior
to exercise [36], sham laser [11], or no treatment [35].
In a fourth laser study, laser was beneficial versus sham
laser at intermediate time points [not at the endpoint],
Table 1 Basic study data (Continued)
Tsai
2009 [48]
China
Good (6)
20 + 21 1) BCa Tx
2) Affected arm circumference ≥
2 cm than unaffected arm
1)≥ 3 month post-BCa Tx
2) 4 week after control period
3) SE Dx/NR
Inclusion:
- unilateral SE ≥ 3 months
Exclusion:
- active cancer
- use of diuretics or other SE
influencing drugs
- skin disease
- decreased arm motion
Wilburn
2006 [49]
††
U.S.
Good (7)
5 + 5 1) BCa Tx
2) Affected arm volume ≥ 20%
than unaffected arm
1) 34 ± 34 month
2) 0-5 month after SE onset
3) SE Dx/NR
Exclusion:
- bilateral SE
- active cancer or infection
- venous obstruction or active
thrombophlebitis
- pulmonary edema
- congestive heart failure
- history of pulmonary embolism
- contraindications to Tx
Williams
2002 [50]
††
U.K.
Fair (4)
15 + 16 1) BCa Tx
2)> 10% excess volume measured
two times
1)> 3 month
2)> 3 month
3) SE Dx/NR
Exclusion:
- active cancer
- use of edema-influencing
drugs
Observational
Balzarini
1993 [51]
Italy
Good (8)
50 + 100 1) BCa Tx
2)% difference between arms: ≤
6.5% (mild), 6.5 to 13%
(moderate), ≥ 13% (severe)
1) IG: 3-52 month; CG: 5-57 month
2) NR
3) SE Dx/NR
Exclusion:
- Tx with regional RT
Berlin
1999 [50]
Sweden
Fair (6)
28 + 8 +19 1) BCa Tx
2) Affected arm volume ≥ 100 ml
than unaffected arm
1) NR
2) NR
3) SE Dx/NR
NR
Brambilla
2006 [53]
Italy
Good (8)
50 + 15 1) SE due to Kaposi’s sarcoma
2) Grade II SE according to ISL
1) NR
2) NR
3) SE Dx/NR
Inclusion:
- SE below knee
Frischenschlager
1991 [54]
Austria
Fair (5)
15 + 15 1) BCa Tx
2) NR
1) ~5 year post-BCa Tx
2) NR
3) SE Dx/NR
Inclusion:
-female
Johansson
1999 [55]
Sweden
Fair (6)
20 + 18 1) BCa Tx
2) Affected arm volume ≥ 10%
than unaffected arm
1) NR
2) NR
3) SE Dx/arm swelling resolution
Exclusion:
- previous contralateral breast
disease
- comorbidity affecting swollen arm
- treatment ≤ 6 months (except
compression sleeve)
Pinell
2007 [56]
U.S.
Good (7)
16 + 56 1) BCa Tx
2) Affected arm circumference ≥
2 cm than unaffected arm
1) NR
2) NR
3) SE Dx/NR
Inclusion:
- referral to specific clinics
BCa Breast Cancer; BMI Body Mass Index; CDT Complex Decongestive Therapy; CG control group; CT chemotherapy; Dx Diagnosis; IG intervention group; ISL
International Society of Lymphology; mo: months; NR Not Reported; RT Radiation Therapy; RCT Randomized Control Trial; SE Secondary Lymphedema; Tx
Treatment; UE: Upper extremity; wk week; yr year
†Rating (scale score)-RCT Jadad: poor (1-3), fair (4-5), good (6-8); Observational NOS: poor (0-3), fair (4-6), good (7-9)
††Crossover RCT (all other RCTs were randomized, parallel group)
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Study 1) Patient Outcomes
Treatment Protocols Length
of
Follow-
up
Tx-related Harms?
2) Results
RCT
Andersen IG: standard care + MLD + self-massage 1) Limb volume, self-reported SE symptoms 12
month
NR
2000 [21] (standard care: compression garment +
exercise instruction + skin care)
Denmark 2) NS
CG: standard care
Bertelli IG: sleeve (6 h/day for 6 mths) + IPC (2 cycles
of 2 week spaced by 5 week interval
1) Limb circumference ≥ 25% compared to
baseline
6
month
NR
1991 [22]
Italy CG: sleeve (6 h/day for 6 months) 2) NS
Bialoszewski IG: Kinesiotaping (10 days) + standard
physiotherapy (not described)
1) Limb circumference 10 days NR
2009 [23]
Poland CG: Lymphatic drainage (1 × /day × 10 days)
+ standard physiotherapy (not described)
2) Significant reduction in limb
circumference with kinesiotaping
Carati IG: LLLT (9 sessions, 17 min each, 3 × /week
× 3 week; 8-week rest and repeat)
1) Limb circumference and volume 24
month
NR
2003 (11)
Australia CG: Sham LLLT 2) NS
(9 sessions as above; 8-week rest) + ‘active’
LLLT (as above)
Damstra IG: Low-stretch bandage 1) Limb volume, pain and discomfort 24 h Patients with high
pressure bandages
reported more pain and
discomfort
2009 [24]
Netherlands CG: High-stretch bandage 2) NS (volume)
Didem IG: MLD + compression garment + exercise +
skin care
1) Limb circumference, range of motion 4 week NR
2005 [25]
Turkey CG: Physiotherapy (bandage + limb elevation
+ exercises) + compression garment +
exercise + skin care
2) Greater decrease in circumference in IG
(p < 0.05), NS (ROM)
Dini IG: IPC (2 cycles over 2 week; each cycle
separated by 5-week interval)
1) Limb circumference 9 week No harms
1998 [26]
Italy CG: Skin care, prophylaxis 2) NS
Hayes IG: Aerobic and resistance exercise (12 week) 1) Bioimpedance, perometry 12
week
Swelling (n = 1)
2009 [27]
Australia CG: NR 2) NS
Hou IG: BMSC + compression garment 1) Limb volume, self-reported pain 52
week
NR
2008 [28]
China CG:CDT (MLD + compression therapy +
exercise)
2) Volume and pain reductions greater in
BMSC group at 52 week (p < 0.05)
Oremus et al. BMC Cancer 2012, 12:6
http://www.biomedcentral.com/1471-2407/12/6
Page 8 of 15Table 2 Data extraction for key questions (Continued)
Irdesel IG: Exercise + compression garment 1) Limb circumference, shoulder range of
motion
6
month
NR
2007 [29]
Turkey CG: Exercise 2) NS
Jahr IG: low-intensity electrostatic field (2-3
×/week × 4 week) + MLD
1) Visual analogue pain scale 8 week NR
2008 [30]
Germany CG: MLD 2) NS
Johansson IG: IPC (2 h/day, 5 days/week for 2 week) +
compression garment
1) Limb volume 2.5 year NR
1998 [31]
Sweden CG: Vodder MLD + compression garment 2) NS
Kaviani IG: LLLT (3 × /week × 3 week; 8 week
interval, then repeat same protocol × 3
week)
1) Limb circumference, visual analogue pain
scale
22
week
NR
2006 [32]
Iran CG: Sham laser 2) IG more efficacious than CG, but authors
report no p-values
Kessler IG: Daily physiotherapy exercises + MLD 1) Limb volume NR NR
2003 [33]
Switzerland CG: Daily physiotherapy exercises 2)% volume reduction-IG vs. CG (6.4% vs.
0.1%, p = 0.011)
Kozanoglu IG: Laser (20 min/3 × wk × 4 week) +
exercise + skin care
1) Limb circumference, visual analogue pain
scale, grip strength
12
month
None
2009 [34]
Turkey CG: IPC (2 h at 60 mmHg × 2) IG improved over CG on circumference (p
= 0.02), pain and grip strength (NS)
20 sessions over 4 week) + exercise + skin
care
Lau IG: LLLT 3 × /week for 4 week 1) Limb volume, tissue resistance, DASH
score
8 week NR
2009 [35]
China CG: no Tx 2) Mean volume less in IG (p = 0.04), greater
tissue resistance in IG at 3 of 4 sites (p <
0.05), DASH (NS)
Maiya IG: LLLT (34 min/day for 10 days) + exercise
(after laser)
1) Limb circumference, pain scale 10 days None
2008 [36]
India CG: Compression garment (10 days) +
exercise
2) IG improved over CG on both outcomes
(p < 0.05)
McKenzie IG: Stretching, resistance, and aerobic exercise
training (3 × /week for 8 week
1) Arm circumference and volume, quality-
of-life (SF-36 scale)
8 week NR
2003 [37]
Canada CG: No Tx 2) NS (all outcomes)
McNeely IG: MLD (5 days/week × 4 week) +
bandaging
1) Limb circumference and volume 4 week Skin reaction (n = 1),
bandage discomfort (n =
1)
2004 [38]
Canada CG: Bandaging 2) NS
Pilch Different IPC protocols (4 groups): 1) Limb volume 5 week NR
2009 [39] -single chamber, 90 s on: 90 sec off
Poland -3 chamber, 90 sec on: 90 sec off 2) NS
-single chamber, 45 sec on: 15 sec off
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-3 chamber, 45 sec on: 15 sec off
Radakovic IG: IPC (60 min/day × 10 days) +
compression bandage
1) Change in arm volume (limb
circumference)
10 days NR
1998 [40]
Yugoslavia CG: MLD (30 min/day × 10 days) +
compression bandage
2) Circumference reduction greater in IG vs.
CG (2.24 cm vs. 0.95; p < 0.05)
Schmitz IG: Weight lifting (supervised for13 week,
unsupervised for 39 week) + compression
garment during exercise
1) Limb volume 12
month
Authors report no serious
harms
2009 [41]
U.S. CG: 1-year fitness membership and 13 week
of supervised instruction (not mandatory)
2) NS
(companion
Schmitz [42])
Shaw IG: Dietary advice for weight loss 1) Limb volume 12
week
NR
2007 [43]
U.K. CG: Healthy eating booklet + compression
garment
2) Significant reduction in SE arm volume IG
vs. CG (7% vs. 3% reduction: p < 0.05)
Shaw IG: Weight reduction-reduced energy intake
OR low fat diet-no reduced energy intake (2
groups)
1) Limb volume 24
week
NR
2007 [44]
U.K. CG: No Tx 2) NS
Sitzia IG: MLD (40-80 min 5 × wk × 2 week) 1) Limb volume 2 week NR
2002 [45]
U.K. CG: SLD (20 mins 5 × wk × 2 week) 2) NS
Szuba IG: MLD (daily, self-administered) +
compression garment
1) Limb volume, tonometry, range of
motion
6
month
None
2002 [47]
U.S. CG: As above + IPC (1 h daily at 40-50
mmHg)
2) Greater mean volume reduction with IPC
(p < 0.05); NS (tonometry, range of motion)
Szuba IG: MLD (daily) + IPC (30 min at 40-50
mmHg) + compression garment
1) Limb volume, tonometry 30 days Repetitive headache and
small blood pressure
increase during IPC (n = 1)
2002 [46]
U.S. CG: MLD (daily) + compression garment 2) NS
(Maintenance therapy-IG & CG: compression
garment + self-administered MLD)
Tsai IG: Kinesiotape bandage 1) Limb volume and circumference,
symptom severity on visual analogue scales,
QoL
3
month
NR
2009 [48]
China CG: Short-stretch bandage 2) NS
(IG & CG: MLD + IPC + exercise)
Wilburn IG: IPC (1 h/day) 1) Limb volume, QoL 42 days NR
2006 [49]
U.S. CG: Self-message (1 h/day) + compression
garment
2) Mean volume reduction greater in IG
(-208 ml vs.
+ 52 ml; p = 0.007), NS (QoL)
Williams IG: MLD (daily × 3 week) 1) Limb volume, caliper creep, dermal
thickness, QoL
12
week
NR
2002 [50]
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Page 10 of 15although the study authors did not provide quantitative
statistical comparisons of the intermediate data [32].
Authors reported conflicting dieting results. One study
showed no improvement with low fat or low caloric
diets [44], while another showed improvement when
dietary advice supplemented use of elastic sleeves [44].
Poor quality trials were more likely to suggest treat-
ment benefits in experimental groups. Two RCTs
Table 2 Data extraction for key questions (Continued)
U.K. CG: SLD (daily × 3 week) 2) NS (limb volume, caliper creep), no
intergroup differences reported in article
(dermal thickness, QoL)
Observational
Balzarini IG: Ultrasound 1) Limb volume 12
month
NR
1993 [51] (2 cycles at 4 month intervals-one cycle =
10-30 min session)
Italy 2) NS
CG: IPC (6 h/day × 5 days once every 4
month for 12 month)
Berlin IG 1: IPC (90-120 mmHg for 20-30 min 2 ×
/day 5 day/week) + compression garment
(25-50 mmHg × 4 week)
1) Limb volume 5 year NR
1999 [52]
Sweden IG 2: IPC (80 mmHg ≥ 20 min/day × 4 week) 2) NS
CG: Compression garment (25-50 mmHg × 4
week)
Brambilla IG: Compression garment (custom-made,
mean pressure = 40 mmHg, worn morning-
to-night, changed every 6 month)
1) Limb volume IG:
Mean
66
week
NR
2006 [53]
Italy CG: No Tx 2) IG: 30/50 mean reduction = 9.3 ml; 20/50
mean increase = 78.7 ml
CG:
Mean
64
week
CG: 15/15 mean increase = 29.6 ml
(p < 0.0001 between groups)
Frischenschlager IG: Psychosocial therapy and exercise (2 h/
week × 10 week) + MLD (3 × /day × 10
week) + compression stocking during day
1) Psychic well being and physical
complaints scales
10
week
NR
1991 [54]
Austria CG: As above except for psychosocial therapy 2) Improved psychic well-being in IG (p =
0.02), NS (physical complaints)
Johansson IG: Compression bandage (2 week) + MLD
(45 min/day × 5 days in wk 3)
1) Limb volume, body weight, pain/
heaviness/tension using visual analogue
scales
19 days NR
1999 [55]
Sweden CG: Compression bandage (2 week) 2) NS (mean volume reduction, body
weight, pain/heaviness/tension),% volume
decrease favored IG (11% vs. 4%; p = 0.04)
Pinell IG: CDT (MLD + bandaging; MLD modified
for patients with axillary or inguinal disease)
1) Limb volume 39
month
NR
2007 [56]
U.S. CG: As above (no modified MLD) 2) NS
BMSC Bone Marrow Stromal Cell Transplantation; CDT: Complex Decongestive Therapy; CG: Control Group; DASH: Disability of Arm Shoulder and Hand; hr hour(s);
IG Intervention Group; IPC Intermittent Pneumatic Compression; LLLT Low-level Laser Therapy; MLD Manual Lymph Drainage; mo: month(s); NR Not Reported; NS
No Statistically Significant Difference Between Groups; QoL Quality of Life; RCT Randomized Control Trial; ROM Range of Motion; SE Secondary Lymphedema; SF-
36 Short Form 36; SLD Simple Lymphatic Drainage; Tx Treatment; wk week(s); yr year(s).
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arm circumference when compared to MLD [40] or
laser [34]. A study of bone marrow stromal cell trans-
plantation versus decongestive therapy reported greater
reductions in excess arm volumes with transplant (i.e.,
81% vs. 55%; p < 0.001) [28].
The six observational studies examined a mixed group
of treatments and found equivocal results: ultrasound
was no different than IPC in reducing arm circumfer-
ence [51], modified MLD reduced SE volume by 22%
relative to standard MLD (authors did not report p-
values) [56], group talks and exercise sessions added to
MLD and compression stockings improved ‘psychic
well-being’ (p < 0.05) yet made no difference in physical
complaints [54], and persons with Kaposi’s sarcoma who
wore daily compression stockings had reductions in
limb volume versus persons who wore no stockings (p <
0.001; authors failed to report the size of the treatment
effect) [53]. Persons receiving MLD in addition to com-
pression bandaging experienced less pain than persons
receiving bandaging alone (p < 0.03), but the results
showed no statistically significant reductions in absolute
limb volume (p = 0.07) [55]. The final observational
study compared sleeve to IPC and the authors found no
significant differences in volume reductions between
groups (the authors did not provide quantitative data)
[52].
Some studies showed a loss of benefit by the end of
the follow-up period. One observational study of elastic
sleeve versus IPC found that both groups had returned
to baseline levels within 4 to 12 weeks post-treatment
[52]. Another study suggested a superior response to
laser compared with sham treatment at 3 weeks follow-
ing the last laser treatment. This benefit was lost after 7
weeks [32].
Considering the chronicity of SE, very few studies had
long-term follow-ups. Eight of 36 studies reported out-
comes at 6 months or more, with benefits shown to last
for up to 1 year in some cases, usually with concomitant
use of maintenance therapy (e.g., elastic sleeve).
What harms are associated with conservative treatments
for SE?
Harms were sporadically reported in the extracted stu-
d i e s .O n l y1 7o f3 0R C T sr e p o r t e dh a r m s
[11,23-27,32-34,36,38,43-47,49]. The majority of harms
were related to disease recurrence, not SE.
Some studies mentioned specific harms from therapy.
These harms were rare, occurring in less than 1% of
patients. Harms included infection, dermatitis [11,38],
arm thrombosis [11,44], headache with elevated blood
pressure [46], and arm pain [38]. None of these harms
had major clinical impacts in any of the studies.
Only two studies compared harms between treat-
ments. In an RCT evaluating bandages, subjects getting
high-pressure bandages reported more pain and discom-
fort than subjects getting low pressure bandages,
although the harms were measured using an invalidated
scale [24]. A similar scale was used in an RCT compar-
ing kinesiology tape with short stretch bandaging: sub-
jects in the kinesiology tape group reported greater
wound development than subjects in the bandage group
(p = 0.013) [48].
No studies reported on factors that may increase the
risk of harms associated with treatment.
Non english-language studies
We included eight non-English-language studies. All
eight studies were observational and involved breast
cancer survivors with upper limb SE. Sample sizes ran-
ged from 30 [57,58] to 440 [59]. Lengths of follow-up,
where reported, ranged from 28 days [57] to 10 years
[59].
Three studies examined single modality treatments:
self-administered MLD versus an unspecified compara-
tor, with improved arm function in the MLD group
[60]; MLD delivered via the ‘Asdonk standard’ method
versus ‘non-Asdonk MLD’, with greater reductions in
arm volume in the Asdonk group (the authors described
the Asdonk method, but did not reference the method,
nor did they provide quantitative statistics or p-values)
[57]; and single- versus multi-chamber IPC, with no dif-
ferences in SE severity between groups at the end of fol-
low-up [61].
Three studies investigated multi-modal treatments:
multi-layer bandaging and MLD versus simplified ban-
daging and MLD, with larger decreases in edema occur-
ring in the simplified bandaging group [62]; MLD, IPC,
and exercise in two groups, with bandage added to one
group, but no intergroup comparisons [58]; and IPC,
IPC plus muscle electrostimulation, IPC plus magnetic
therapy, or IPC plus both electrostimulation and mag-
netic therapy, with the largest percent change in limb
volume occurring in the last group (p < 0.05) [59].
Two studies examined whether the time of treatment
initiation affected outcomes. The first study compared
treatment initiated within 1 year of breast cancer sur-
gery to initiation within 1 or 2 years. Treatment in both
groups was a combination of MLD, IPC, bandage, and
exercise. Faster reduction of arm swelling was observed
in the group with earlier treatment initiation [63]. Con-
versely, the second study found no differences between
groups when treatment was initiated 3 months versus
12 months following SE diagnosis. The treatment regi-
m e ni nt h i ss t u d yw a sp h y s i c a l therapy, electrostimula-
tion, massage, and IPC [64].
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degree of heterogeneity observed in the English-lan-
guage studies, e.g., different treatment combinations,
varying lengths of follow-up. This heterogeneity pre-
vented us from drawing clear conclusions to answer the
key questions. The non-English articles did not contain
substantive new information to supplement or alter our
English-language findings.
Discussion
Most extracted studies were conducted in persons with
a history of breast cancer. One must be prudent before
generalizing these studies’ results to persons with other
conditions.
Many studies showed that most active treatments
reduced the size of lymphatic limbs, although extensive
study heterogeneity in areas such as length of follow-up,
treatment protocols, comparators, and outcome mea-
sures prevented us from assessing whether any one treat-
ment was superior. The extracted studies did not contain
reports of treatment benefits in any subgroup of patients.
Harms were reported in a small number of studies.
These harms were rare and mild, and unlikely to be
major clinical issues.
The methodological quality of the extracted studies
was generally ‘fair’. The authors of some studies omitted
the reporting of fundamental elements of their research,
such as the blinding of outcome assessors. Quality did
not generally affect our interpretation of answers to the
key questions.
Research recommendations
Treatment protocols should be clearly described in pub-
lished RCT reports (describing the comparator as ‘usual
care’ is insufficient). If researchers believe a priori that
important subgroup effects are possible, then the study
should be powered to detect effects in these subgroups.
Since a multiplicity of outcomes exists in SE research,
researchers should develop a short list of preferred
study outcomes. This will facilitate between-study com-
parisons and help make meta analyses feasible.
Experimental and comparator treatments must be
clearly labeled and the comparator should be a standard
treatment regimen for SE. Although sham treatments (e.
g., laser) may satisfy minimum regulatory requirements
for showing effectiveness, the clinical utility of a novel
treatment is best demonstrated against an accepted
standard treatment. Maintenance therapies, where used,
should be clearly described by study authors. Blinding of
study participants, clinicians, and healthcare profes-
sionals who administer treatment may not be possible
due to the nature of the therapies; however, at a mini-
mum, researchers should blind outcome assessors to
treatment.
To avoid the publication of ambiguous trial reports,
study authors should use existing quality scales
[17-19,65] and the 2010 CONSORT statement for RCTs
[66] as templates for producing RCT manuscripts. One
of the extracted studies provides a good example of
reporting an RCT’s results [41].
Most of the extracted studies involved SE to the upper
extremities. Few studies involved lower limb SE, despite
its high incidence from cancer treatment [4]. More
RCTs should be conducted in persons with SE of the
lower limbs.
Another issue concerns whether treatment for the
condition preceding SE would affect outcomes of con-
servative therapy for SE. For example, would patients
treated with radiation therapy for breast cancer respond
better to MLD than patients treated with lymphadenect-
omy? Research into this area could provide evidence to
guide selection of SE therapy.
Conclusions
Scientists have conducted a great deal of research into
the treatment of SE. However, the literature contains no
evidence to suggest the most effective treatment. Harms
from treatment are minor and likely to have little clini-
cal impact. The field of research into treating SE is open
to advancement and we hope this review will guide
future research in the area.
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